Cardiovascular risk profile in patients treated with sirolimus after renal transplantation

20Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Renal transplant patients are inherently predisposed to cardiovascular disease (CVD) as a result of prolonged exposure to multiple cardiovascular risk factors. Approximately one half of all late graft losses are due to death with a functioning graft, and CVD is the most frequent cause of death with a functioning graft among these patients. Immunosuppressive therapies associated with a reduced burden of risk for CVD would therefore greatly decrease post-transplantation morbidity and mortality. The nephrotoxic effects observed with the use of calcineurin inhibitors (CNIs), such as cyclosporine (CsA), run counter to the goal of renal transplant therapy. Sirolimus, a more recent immunosuppressive agent with a unique mechanism of action, offers an alternative to CsA. Recent data from a 4-year study investigating early CsA withdrawal from a sirolimus-CsA-steroid (SRL-CsA-ST) combination demonstrated significantly better renal function, lower blood pressure, and improved graft survival after CsA withdrawal. During that trial, the increase in serum lipids induced by sirolimus was generally manageable with lipid-lowering therapy. Further investigation is warranted to evaluate the value of CNI-free therapy compared with CNI-based regimens in reducing cardiovascular risk factors and improving patient and graft survival.

References Powered by Scopus

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery

4190Citations
N/AReaders
Get full text

Clinical epidemiology of cardiovascular disease in chronic renal disease

3121Citations
N/AReaders
Get full text

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study

880Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cardiovascular complications after renal transplantation and their prevention

384Citations
N/AReaders
Get full text

Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells

75Citations
N/AReaders
Get full text

Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat

64Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Morales, J. M. (2005). Cardiovascular risk profile in patients treated with sirolimus after renal transplantation. In Kidney International, Supplement (Vol. 67). Blackwell Publishing Inc. https://doi.org/10.1111/j.1523-1755.2005.09315.x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

60%

Researcher 2

40%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

67%

Social Sciences 1

11%

Neuroscience 1

11%

Psychology 1

11%

Save time finding and organizing research with Mendeley

Sign up for free